| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MLKL[1]
|
|---|---|
| ln Vitro |
As a specific inhibitor of MLKL, MLKL-IN-2 exerts biological effects by targeting MLKL, a key effector protein in the necroptosis pathway. Although its exact IC₅₀ value has not been publicly reported, similar MLKL inhibitors have been shown to alter intracellular trafficking, inhibit the constitutive release of extracellular vesicles (EVs), reduce the expansion of glioblastoma stem-like cells (GSCs), and increase GSC death in vitro, while also potentiating the efficacy of temozolomide, a chemotherapeutic agent. Given its mechanism of action as an MLKL inhibitor, it is inferred to interfere with MLKL-mediated necroptosis and related cellular processes, though direct experimental data on its specific in vitro activity (such as anti-necroptotic potency in various cell lines) remains limited to patent information without detailed public reports.
|
| ln Vivo |
Publicly available data on the in vivo activity of MLKL-IN-2 is scarce, with no direct reports on its pharmacodynamic effects in animal models. However, pharmacological inhibition of MLKL has been demonstrated to reduce tumor burden and the level of plasmatic extracellular vesicles in in vivo studies of glioblastoma, suggesting a potential therapeutic role for MLKL inhibitors in tumor treatment. As a specific MLKL-targeting agent, MLKL-IN-2 may exhibit similar in vivo effects, such as suppressing MLKL-related pathological processes (e.g., tumor growth, inflammatory responses) through inhibiting MLKL activity, but further in vivo experiments are required to confirm its efficacy, optimal dosage, and therapeutic window.
|
| References |
| Molecular Formula |
C26H25N5O
|
|---|---|
| Molecular Weight |
423.509605169296
|
| Exact Mass |
423.205
|
| CAS # |
899759-16-1
|
| PubChem CID |
7593182
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=C2C=CC=CC2=C1)NC1=CC=CC(=C1)C1=CC=C(N=N1)N1CCN(C)CC1
|
| InChi Key |
CVHOXUUPSXOTPM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H25N5O/c1-30-13-15-31(16-14-30)25-12-11-24(28-29-25)21-7-4-8-23(18-21)27-26(32)22-10-9-19-5-2-3-6-20(19)17-22/h2-12,17-18H,13-16H2,1H3,(H,27,32)
|
| Chemical Name |
N-[3-[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]phenyl]naphthalene-2-carboxamide
|
| Synonyms |
MLKL-IN-2; MLKL-IN 2; MLKL-IN2; 899759-16-1; TCMDC-125349; N-(3-(6-(4-methylpiperazin-1-yl)pyridazin-3-yl)phenyl)-2-naphthamide; N-{3-[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]phenyl}naphthalene-2-carboxamide;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (23.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3612 mL | 11.8061 mL | 23.6122 mL | |
| 5 mM | 0.4722 mL | 2.3612 mL | 4.7224 mL | |
| 10 mM | 0.2361 mL | 1.1806 mL | 2.3612 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
